Imatinib use in the management of a patient with Doege–Potter syndrome

• Autores: Paz-Ibarra, Jose, Lu-Antara, Jose, Uscamayta, Brenda-Erendida, Martinez-Auris, Jhancy, Valencia-Rivera, Miriam, Sáenz-Bustamante, Sofía, Delgado-Rojas, Marialejandra, Salcedo-Vasquez, Julia, Concepción-Zavaleta, Marcio
• Formato: artículo
• Fecha de Publicación: 2023
• Institución: Universidad Privada Norbert Wiener
• Repositorio: UWIENER-Institucional
• Lenguaje: inglés
• OAI Identifier: oai:repositorio.uwiener.edu.pe:20.500.13053/9303
• Enlace del recurso: https://hdl.handle.net/20.500.13053/9303
• Nivel de acceso: acceso abierto
• Materia: Doege–Potter, Solitary fibrous tumor; 3.03.00 -- Ciencias de la salud

“Doege–Potter syndrome (DPS) is a paraneoplastic syndrome characterized by nonislet cell tumor hypoglycemia due to a solitary fibrous tumor, which produces insulin-like growth factor II. In this report, we present the case of a 67-year-old male with recurrent and refractory hypoglycemia due to DPS successfully treated with imatinib. He initially presented with neuroglycopenic symptoms and dyspnea secondary to a giant tumor in the left hemithorax, which was totally resected. During follow-up, 7 years later, he presented with thoracoabdominal tumor recurrence associated with severe hypoglycemia and underwent subtotal tumor resection, with a subsequent improvement of symptoms. The following year, he had a recurrence of his intra-abdominal tumor, which was unresectable, associated with severe hypoglycemia refractory to dextrose infusion and corticosteroids, thus receiving imatinib with a favorable response. The clinical presentation, diagnostic approach, progression of the disease, and response to treatment with imatinib in the management of a patient with large, recurrent, and unresectable mesenchymal tumors with insulin-like growth factor-2 secretion causing hypoglycemia highlight the importance of this case report“